Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 2/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP12 | P39900 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29501710 | 0.86 | SMN1; SMN2 (0.48) | PARP10IDO1ALDH1A1PKMCYP1A2 | |
| SCHEMBL7765576 | 0.84 | MAPT (0.56) | PARP10IDO1MMP1MMP2MMP9 | |
| SCHEMBL7760184 | 0.82 | ALDH1A1 (0.56) | PARP10IDO1MMP1MMP2MMP9 | |
| SCHEMBL6702870 | 0.82 | MMP1 (0.54) | PARP10IDO1MMP1MMP2MMP9 | |
| SCHEMBL30429390 | 0.82 | ALDH1A1 (0.56) | PARP10IDO1MMP1MMP2MMP9 | |
| SCHEMBL29272771 | 0.82 | MMP1 (0.41) | PARP10IDO1MMP1MMP2MMP9 | |
| SCHEMBL2548713 | 0.81 | TAAR1 (0.50) | PARP10IDO1MMP1MMP2MMP9 | |
| SCHEMBL10800307 | 0.81 | ALDH1A1 (0.56) | PARP10IDO1MMP1MMP2MMP9 | |
| SCHEMBL777869 | 0.81 | MAPT (0.57) | PARP10IDO1MMP1MMP2MMP9 | |
| SCHEMBL6176778 | 0.81 | ALDH1A1 (0.55) | PARP10IDO1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 508 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257031-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2025-08-14 | — | — | US | claimed |
| US-12291495-B2 | Process for the production of substituted 2-[2-(phenyl)ethylamino] alkaneamide derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2025-05-06 | — | — | US | claimed |
| US-20220185766-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2022-06-16 | — | — | US | claimed |
| EP-3956296-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2022-02-23 | — | — | EP | claimed |
| WO-2020212352-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2020-10-22 | — | — | WO | claimed |
| EP-3725769-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2020-10-21 | — | — | EP | claimed |
| WO-2026089784-A2 | COMPOUNDS AND COMPOSITIONS FOR CONJUGATION TO BIOLIGANDS FOR IMAGING AND RADIOPHARMACEUTICAL APPLICATIONS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20250257031-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2025-08-14 | — | — | US | disclosed |
| WO-2025151874-A1 | INDOLE ALKALOID ANTIPLASMODIAL AGENTS AND PREPARATION THEREOF | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| US-12291495-B2 | Process for the production of substituted 2-[2-(phenyl)ethylamino] alkaneamide derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2025-05-06 | — | — | US | disclosed |
| WO-2025038960-A1 | OLIGONUCLEOTIDES CONTAINING A LIGAND AT AN INTERNAL POSITION | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| US-12083186-B2 | Methods for assembling scavenging particles | NANOTICS, LLC (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240269319-A1 | METHODS FOR ASSEMBLING SCAVENGING PARTICLES | NANOTICS, LLC | 2024-08-15 | — | — | US | disclosed |
| WO-2007117639-A9 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | HARVARD COLLEGE (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2007117639-A2 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-10-18 | — | — | WO | disclosed |
| CN-101010336-A | Peptide antibiotics and process for preparing same | BIOSOURCE PHARM INC (US) | 2007-08-01 | — | — | CN | disclosed |
| WO-2007013965-A2 | SYNTHESIS OF SCABRONINES AND ANALOGUES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2006138380-A2 | AMINE-CONTAINING LIPIDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006124902-A2 | SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGUES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006113615-A2 | ANTI-MICROBIAL AGENTS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185766-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVES | HRH3, CYP2A7, HRH4 | PARP10 1129/4885IDO1 3435/4885MMP1 4111/4885 |
| US-20250257031-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVES | HRH3, HRH4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PARP10 1275/4885IDO1 3371/4885MMP1 4095/4885 |
| US-12291495-B2 | Process for the production of substituted 2-[2-(phenyl)ethylamino] alkaneamide derivatives | HRH3, CYP2A7, HRH4 | PARP10 1129/4885IDO1 3435/4885MMP1 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.